tisagenlecleucel
novartis
['leusm', 'leukemia']
congress #eha2022 | susana rives presented eliana phase ii study results of tisagenlecleucel in heavily pretreated pediatric and adult pts with r/r b-all. n=97, orr=82%, 5 yr rfs=44%, median os not reached #allsm #leusm #leukemia 
A global education platform providing clinical updates on acute lymphoblastic leukemia. #leusm #allsm